Trials / Completed
CompletedNCT00169572
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
See Detailed Description
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 492 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to assess the safety and efficacy of an investigational agent administered in addition to a standard anti-emetic regimen for the treatment of chemotherapy induced nausea and vomiting.
Detailed description
Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aprepitant | |
| DRUG | Ondansetron | |
| DRUG | GW679769 | |
| DRUG | Dexamethasone |
Timeline
- Start date
- 2005-02-01
- First posted
- 2005-09-15
- Last updated
- 2010-05-10
Locations
51 sites across 19 countries: Argentina, Austria, Belgium, Chile, Croatia, Czechia, Hong Kong, Hungary, Italy, Mexico, Netherlands, Pakistan, Peru, Philippines, Poland, Romania, Singapore, Slovakia, Taiwan
Source: ClinicalTrials.gov record NCT00169572. Inclusion in this directory is not an endorsement.